Table 3.
anova for impact of fasting/fed state on relevant ponatinib pharmacokinetic parameters
| 90% CI | |||||
|---|---|---|---|---|---|
| Reference treatment | Test treatment | Ln-transformed variable | Estimated mean ratio (T/R), % | Lower limit | Upper limit |
| Fasted | High-fat meal | AUC0-∞ | 109·55 | 105·85 | 113·38 |
| AUC0-t | 109·50 | 105·83 | 113·29 | ||
| Cmax | 94·22 | 89·70 | 98·97 | ||
| Fasted | Low-fat meal | AUC0-∞ | 97·85 | 94·54 | 101·27 |
| AUC0-t | 97·73 | 94·46 | 101·11 | ||
| Cmax | 94·29 | 89·77 | 99·05 |
CI, confidence interval; T/R, test/reference; AUC0-∞, area under the concentration–time curve from zero to infinity; AUC0-t, area under the concentration–time curve from time zero to the last measurable time point; Cmax, maximum plasma concentration.